(Q44584667)

4 December 2017

title

Effects of age on prognosis with imatinib mesylate therapy for patients with Philadelphia chromosome-positive chronic myelogenous leukemia (English)

1 reference

4 December 2017

1 reference

1 reference

11

Hagop Kantarjian

1 reference

4 December 2017

9

Alessandra Ferrajoli

1 reference

4 December 2017

7

Stefan Faderl

1 reference

4 December 2017

10

William Wierda

1 reference

4 December 2017

1

Jorge Cortes

1 reference

4 December 2017

3

Susan O'Brien

1 reference

4 December 2017

5

Mary Beth Rios

1 reference

4 December 2017

4

Francis Giles

1 reference

4 December 2017

Guillermo Garcia-Manero

series ordinal

8

object named as

Guillermo Garcia-Manero

1 reference

4 December 2017

2

Moshe Talpaz

1 reference

4 December 2017

6

Jianquin Shan

1 reference

4 December 2017

language of work or name

English

0 references

publication date

1 September 2003

1 reference

4 December 2017

1 reference

4 December 2017

volume

98

1 reference

4 December 2017

issue

6

1 reference

4 December 2017

page(s)

1105-1113

1 reference

Proposal for a simple synthesis prognostic staging system in chronic myelogenous leukemia

4 December 2017

cites work

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11629

7 January 2021

A new prognostic score for survival of patients with chronic myeloid leukemia treated with interferon alfa. Writing Committee for the Collaborative CML Prognostic Factors Project Group.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11629

7 January 2021

Result of interferon-alpha therapy in patients with chronic myelogenous leukemia 60 years of age and older

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11629

7 January 2021

Prolonged survival in chronic myelogenous leukemia after cytogenetic response to interferon-alpha therapy. The Leukemia Service

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11629

7 January 2021

Interferon alfa-2a as compared with conventional chemotherapy for the treatment of chronic myeloid leukemia

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11629

7 January 2021

Hematologic and cytogenetic responses to imatinib mesylate in chronic myelogenous leukemia

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11629

7 January 2021

Imatinib induces durable hematologic and cytogenetic responses in patients with accelerated phase chronic myeloid leukemia: results of a phase 2 study

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11629

7 January 2021

Imatinib mesylate (STI571) therapy for Philadelphia chromosome-positive chronic myelogenous leukemia in blast phase

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11629

7 January 2021

Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11629

7 January 2021

Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11629

7 January 2021

Imatinib mesylate therapy in newly diagnosed patients with Philadelphia chromosome-positive chronic myelogenous leukemia: high incidence of early complete and major cytogenetic responses

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11629

7 January 2021

Characteristics of accelerated disease in chronic myelogenous leukemia

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11629

7 January 2021

Chronic myelogenous leukemia in blast crisis. Analysis of 242 patients.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11629

7 January 2021

Determinants of prognosis in late chronic-phase chronic myelogenous leukemia

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11629

7 January 2021

Long-term follow-up results of alpha-interferon-based regimens in patients with late chronic phase chronic myelogenous leukemia

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11629

7 January 2021

Identifiers

DOI

10.1002/CNCR.11629

1 reference

4 December 2017

1 reference